Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 6
2004 3
2005 2
2006 3
2007 4
2008 6
2009 10
2010 10
2011 17
2012 22
2013 24
2014 17
2015 13
2016 6
2017 7
2018 12
2019 13
2020 14
2021 16
2022 11
2023 21
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
308-nm excimer light is effective for palmoplantar pustulosis regardless of the presence or absence of focal infection: Single-center real-world experience of treatment for palmoplantar pustulosis.
Niimura Y, Kamata M, Ishikawa T, Nagata M, Ito M, Watanabe A, Egawa S, Uchida H, Hiura A, Fukaya S, Hayashi K, Fukuyasu A, Tanaka T, Tada Y. Niimura Y, et al. Among authors: tada y. J Dermatol. 2024 Mar 14. doi: 10.1111/1346-8138.17191. Online ahead of print. J Dermatol. 2024. PMID: 38483008
An approach to diagnosis and management of patients with pyoderma gangrenosum from an international perspective: results from an expert forum.
Haddadin OM, Ortega-Loayza AG, Marzano AV, Davis MDP, Dini V, Dissemond J, Hampton PJ, Navarini AA, Shavit E, Tada Y, Yamamoto T, Alavi AA. Haddadin OM, et al. Among authors: tada y. Arch Dermatol Res. 2024 Feb 24;316(3):89. doi: 10.1007/s00403-024-02829-0. Arch Dermatol Res. 2024. PMID: 38400852 No abstract available.
Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S, Okubo Y, Tada Y, Ohtsuki M, Colston E, Napoli A, Shao Y, Banerjee S, Morita A. Imafuku S, et al. Among authors: tada y. J Dermatol. 2024 Mar;51(3):365-379. doi: 10.1111/1346-8138.17074. Epub 2024 Jan 24. J Dermatol. 2024. PMID: 38268101 Clinical Trial.
Author Correction: Efficacy and Safety of Apremilast for the Treatment of Japanese Patients with Palmoplantar Pustulosis: Results from a Phase 2, Randomized, Placebo-Controlled Study.
Terui T, Okubo Y, Kobayashi S, Sano S, Morita A, Imafuku S, Tada Y, Abe M, Yaguchi M, Uehara N, Handa T, Tanaka M, Zhang W, Paris M, Murakami M. Terui T, et al. Among authors: tada y. Am J Clin Dermatol. 2024 Jan;25(1):165-167. doi: 10.1007/s40257-023-00825-0. Am J Clin Dermatol. 2024. PMID: 38060175 Free PMC article. No abstract available.
Crosstalk: keratinocytes and immune cells in psoriasis.
Kamata M, Tada Y. Kamata M, et al. Among authors: tada y. Front Immunol. 2023 Nov 9;14:1286344. doi: 10.3389/fimmu.2023.1286344. eCollection 2023. Front Immunol. 2023. PMID: 38022549 Free PMC article. Review.
Minimum data set for treatment effectiveness in pyoderma gangrenosum (MIDSTEP): an international protocol of an e-Delphi study to develop a clinical physician-driven treatment effectiveness registry on behalf of the UPGRADE initiative.
Haddadin OM, Jacobson ME, Chen DM, Croitoru DO, Dissemond J, Gontijo JRV, Hampton PJ, Kelly RI, Marzano AV, Tada Y, Gerbens LAA, Ortega-Loayza AG. Haddadin OM, et al. Among authors: tada y. Arch Dermatol Res. 2023 Dec;315(10):2913-2919. doi: 10.1007/s00403-023-02729-9. Epub 2023 Sep 27. Arch Dermatol Res. 2023. PMID: 37755505
205 results